comprehensive -WSS

comprehensive

author：entertainment 2025-09-03 07:44:51 - browse：51936

Adam's take main illustration — Molly Ferguson/STAT

Behind the stellar commercial launch of Amylyx Pharmaceuticals’ treatment for ALS lies an uncomfortable question: Does early success of the drug, called Relyvrio, make it more complicated, perhaps impossible, to pull it from the market if we find out next year that it doesn’t work?

On Monday night, Amylyx said Relyvrio sales totaled $22 million in 2022 — a period that covers slightly more than one calendar quarter given the drug’s U.S. approval last September. The company said approximately 1,300 ALS patients were on Relyvrio at the end of December, and it expects that number to at least double by the end of the first quarter.

“We’re probably going to double, closer to triple, our revenue in Q1,” said James Frates, Amylyx’s chief financial officer, speaking on Monday night’s conference call.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： After affirmative action ruling, medical educators look to 'holistic review'
Next article： Did you have Obamacare on your GOP debate bingo card?

WSS

Color Health wants to make cancer screenings convenient

Biogen shutters digital health group, ends Apple study, in cost cutting move

Covid vaccines: Private market messier than government rollout

Mindstrong's demise and the future of mental health care

Address the ethical violations that led to 'Three Identical Strangers'

STAT Virtual Event: How to Increase Diversity in Clinical Trials

knowledge

comprehensive

focus

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Menendez indictment could see pharma lose a key ally

Jerome Adams on the need for new antivirals for Covid

Did you have Obamacare on your GOP debate bingo card?

Psychedelics group wrestles with new pharma identity

Ohio train derailment: Experts on toxic chemical risks

Psychedelics group wrestles with new pharma identity

Laying a path for careers in science

Medicare proposal to cover medical devices draws a mixed reaction

Listen: Who gets the credit for GLP

focus

Medicare isn't yet testing food as medicine

Inequities make cancer less preventable for women: report

Kaiser Permanente unions announce official strike date

Children’s Hospital revives plan for pedestrian bridge

Neuroscience renaissance leads to new crop of psychiatric drugs

Doctor of U.S. President Joe Biden says he is fit for duty

focus

explore

explore

Wikipedia